Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,780 signal articles · 254 in last 24h · 118,087 total before filter · latest 55m ago
254last 24h
1605last 7d
251● bullish (7d)
160● bearish (7d)
205publishers
AllMacro308Earnings667M&A92Regulatory28Product12Analyst24
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Honeywell (HON) Completes Aerospace Spin Off As Standalone Guidance Takes Shape
Simply Wall St.12d agoneutral
Honeywell (HON) Completes Aerospace Spin Off As Standalone Guidance Takes Shape

Honeywell Aerospace, recently spun off from Honeywell International (NasdaqGS:HON), reported its first standalone financial results and issued new guidance. The newly independent aerospace company outlined its operating strategy, including capital allocation plans and priorities for future contract opportunities. Management highlighted recent contract wins and provided an update on the order pipeline as part of its initial outlook to investors. Consider reviewing other established dividend...

On Holding (NYSE:ONON) Stock May Trade At A Premium Following Earnings Next Week
Simply Wall St.12d agoneutral
On Holding (NYSE:ONON) Stock May Trade At A Premium Following Earnings Next Week

On Holding stock has fallen 18.7% year to date, yet its Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market multiples suggest the shares are priced on the rich side. With earnings news approaching and a low overall value score, investors are weighing a discounted cash flow signal against a less generous read from traditional ratios. On Holding is down 18.7% so far in 2026, which puts extra focus on whether the current price offers a margin of safety...

Immunovant Q1 Earnings Call Highlights
MarketBeat12d agoneutral
Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt

Himax Technologies Q2 Earnings Call Highlights
MarketBeat12d agoneutral
Himax Technologies Q2 Earnings Call Highlights

Himax Technologies (NASDAQ:HIMX) reported second-quarter 2026 results that exceeded its prior guidance, as stronger-than-expected automotive integrated-circuit sales lifted revenue, gross margin and profit. Revenue for the quarter totaled $227.4 million, up 14.2% sequentially and 5.9% from a year e